Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic

[1] Bartlett DL(2020)Management of cancer surgery cases during the COVID-19 pandemic: considerations Ann Surg Oncol 27 1717-1720

[2] Howe JR(2017)Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study Ann Surg Oncol 24 418-424

[3] Chang G(2020)The landmark series: neoadjuvant endocrine therapy for breast cancer Ann Surg Oncol 27 3393-3401

[4] Chiba A(2020)Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic NPJ Breast Cancer 6 21-32

[5] Hoskin TL(2010)Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial Ann Surg 252 426-926

[6] Heins CN(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 318 918-121

[7] Hunt KK(1998)A brief tutorial on the development of measures for use in survey questionnaires Organ Res Methods 1 104-1516

[8] Habermann EB(2010)AM last page: survey development guidance for medical education researchers Acad Med 85 925-215

[9] Boughey JC(2018)Surgeon attitudes toward the omission of axillary dissection in early breast cancer JAMA Oncol 4 1511-147

[10] Weiss A(1977)Self-efficacy: toward a unifying theory of behavioral change Psychol Rev 84 191-107

[1] Bartlett DL(2020)Management of cancer surgery cases during the COVID-19 pandemic: considerations Ann Surg Oncol 27 1717-1720

[2] Howe JR(2017)Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study Ann Surg Oncol 24 418-424

[3] Chang G(2020)The landmark series: neoadjuvant endocrine therapy for breast cancer Ann Surg Oncol 27 3393-3401

[4] Chiba A(2020)Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic NPJ Breast Cancer 6 21-32

[5] Hoskin TL(2010)Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial Ann Surg 252 426-926

[6] Heins CN(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 318 918-121

[7] Hunt KK(1998)A brief tutorial on the development of measures for use in survey questionnaires Organ Res Methods 1 104-1516

[8] Habermann EB(2010)AM last page: survey development guidance for medical education researchers Acad Med 85 925-215

[9] Boughey JC(2018)Surgeon attitudes toward the omission of axillary dissection in early breast cancer JAMA Oncol 4 1511-147

[10] Weiss A(1977)Self-efficacy: toward a unifying theory of behavioral change Psychol Rev 84 191-107